why choose us

First received: March 29, 2024

Clinical Trial: A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Hereditary Angioedema (HAE)

Study Type: OBSERVATIONAL


Official Title: The Real-World Effectiveness and Safety of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) for Hereditary Angioedema: An Observational Study in China

Brief Summary: The Chinese health authority has approved lanadelumab to prevent Hereditary Angioedema (HAE) attacks in persons of 12 years and older.It has also approved icatibant to treat acute HAE attacks in persons 2 years and older.One of the main aims of this study is to learn about the number of HAE attacks in 1 month in Chinese persons with HAE during their treatment with lanadelumab.The other main aim is to learn how much time is needed to resolve acute HAE attacks when treated with icatibant.Other aims of this study are…

Read more